15 October 2011 in Molecular Biology of the Cell
Fibroblast growth factor receptor 3 (FGFR3) is a major negative regulator of bone growth that inhibits the proliferation and differentiation of growth plate chondrocytes. Activating mutations of its c isoform cause dwarfism in humans; somatic mutations can drive oncogenic transformation in multiple myeloma and bladder cancer. How these distinct activities arise is not clear. FGFR3 was previously shown to undergo proteolytic cleavage in the bovine rib growth plate, but this was not explored further. Here, we show that FGF1 induces regulated intramembrane proteolysis (RIP) of FGFR3. The ectodomain is proteolytically cleaved (S1) in response to ligand-induced receptor activation, but unlike most RIP target proteins, it requires endocytosis and does not involve a metalloproteinase. S1 cleavage generates a C-terminal domain fragment that initially remains anchored in the membrane, is phosphorylated, and is spatially distinct from the intact receptor. Ectodomain cleavage is followed by intramembrane cleavage (S2) to generate a soluble intracellular domain that is released into the cytosol and can translocate to the nucleus. We identify the S1 cleavage site and show that γ-secretase mediates the S2 cleavage event. In this way we demonstrate a mechanism for the nuclear localization of FGFR3 in response to ligand activation, which may occur in both development and disease.
1 August 2011 in Biochimica et Biophysica Acta (BBA) - Biomembranes
1 December 2018 in Clinical Breast Cancer
1 April 2019 in International braz j urol
Keywords: Prostatic Neoplasms; Dose Hypofractionation; Neoplasm Grading
20 May 2016 in Journal of Clinical Oncology
E16133 Background: SRC is overexpressed in many cancers and promotes growth, angiogenesis and metastasis. We previously reported that RCC expressing higher SRC by immunohistochemistry (IHC) is associated with worse overall survival (OS), and SRC and VHL levels are positively correlated in RCC. We hypothesized that RCC tumors expressing high SRC and VHL (hSRC/hVHL) represent a more aggressive phenotype that is less responsive to therapies given that the presence of VHL suggests an intact VHL/HIF axis. We analysed SRC and VHL expression as well as tumor VHL mutational status in a prospective cohort of mRCC patients (pts). Methods: Pts with mRCC with archival tumor tissue provided written informed consent. Primary and metastatic samples were evaluated for VHL and SRC protein expression by IHC and scored based on intensity and percent staining. The median was used as a cutoff to define high versus low staining for both VHL and SRC. Association was determined using Spearman correlation coefficient. VHL and SRC staining status was analyzed for correlation with OS and time to treatment failure (TTF), defined from initiation of first line systemic therapy to discontinuation from any cause. DNA was extracted from paraffin embedded tumors, PCR amplified and VHL sequenced. Results: 45 nephrectomy and 22 metastatic specimens were available from 54 consented pts. 46 pts (87% clear cell) received systemic therapy (38 VEGF-TKI; 5 mTOR-I; 3 IL-2). 44% harbored hSRC/hVHL. VHL and SRC expression were positively correlated (ρ < 0.0001). On log-rank analysis, hSRC/hVHL was associated with longer TTF (HR 0.43 [0.19, 0.95], ρ = 0.0368) and non-significantly with OS (HR 0.42 [0.15, 1.18], ρ = 0.0889). In multivariate analysis controlling for Heng score and treatment type, hSRC/hVHL was not an independent predictor of TTF. There was no correlation between VHL mutation status and VHL staining. WT-VHL compared to mut-VHLwas marginally associated with longer TTF (median 15.7m vs 5.8m; ρ = 0.0919). Conclusions: hSRC/hVHL was associated with better clinical outcome, but was not an independent predictor when controlled for by Heng score and treatment type. VHL expression by IHC did not correlate with VHL mutation status. The role of SRC and its relation to VHL warrants further investigation.